Core Laboratories (NYSE:CLB) Stock Rating Upgraded by Johnson Rice

Key Points

• Johnson Rice upgraded Core Laboratories from “hold” to “buy” and set a $21.00 price target, implying 67.46% upside from the prior close. Despite the upgrade, the broader analyst consensus remains “Hold.”
• Core Laboratories reported quarterly EPS of $0.11, beating estimates of $0.09, while revenue of $124.61 million fell short of expectations and declined 4.3% year over year.
• CEO Lawrence Bruno purchased 5,000 shares, and institutional investors and hedge funds own 97.81% of the company’s stock.

Core Laboratories (NYSE:CLB - Get Free Report) was upgraded by equities researchers at Johnson Rice from a "hold" rating to a "buy" rating in a research note issued to investors on Thursday, Marketbeat.com reports. The firm presently has a $21.00 price objective on the oil and gas company's stock. Johnson Rice's price target points to a potential upside of 67.46% from the stock's previous close.

Several other research analysts also recently weighed in on the stock. Weiss Ratings upgraded shares of Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Core Laboratories from a "sell" rating to a "hold" rating in a research report on Saturday, August 1st. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $21.00.

Core Laboratories Price Performance

Shares of Core Laboratories stock traded up $0.09 on Thursday, reaching $12.54. The stock had a trading volume of 135,231 shares, compared to its average volume of 590,896. Core Laboratories has a 1 year low of $9.79 and a 1 year high of $20.36. The company has a market cap of $575.40 million, a P/E ratio of 22.39, a price-to-earnings-growth ratio of 3.00 and a beta of 1.03. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. The business's 50 day moving average is $11.64 and its two-hundred day moving average is $14.77.

Core Laboratories (NYSE:CLB - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $124.61 million during the quarter, compared to analysts' expectations of $126.26 million. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. Core Laboratories's revenue for the quarter was down 4.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. As a group, research analysts anticipate that Core Laboratories will post 0.53 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Lawrence Bruno purchased 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The shares were bought at an average price of $10.78 per share, for a total transaction of $53,900.00. Following the acquisition, the chief executive officer directly owned 262,438 shares in the company, valued at $2,829,081.64. This trade represents a 1.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. 1.26% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Core Laboratories

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Core Laboratories in the second quarter valued at about $86,910,000. Heartland Advisors Inc. purchased a new position in Core Laboratories in the 2nd quarter worth approximately $12,329,000. Goldman Sachs Group Inc. boosted its holdings in Core Laboratories by 185.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 845,251 shares of the oil and gas company's stock worth $13,549,000 after acquiring an additional 548,657 shares during the period. Disciplined Growth Investors Inc. MN grew its position in Core Laboratories by 9.7% in the third quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company's stock valued at $73,787,000 after acquiring an additional 528,976 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Core Laboratories during the second quarter valued at approximately $4,675,000. 97.81% of the stock is owned by institutional investors and hedge funds.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company's portfolio spans two primary service lines: reservoir description and production enhancement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source